[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcmtc_5VRfcY4BGV9TTt0SgDPu0XxnuGVWm3_bgz05m0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":54,"rows":61},"Singapore General Hospital",[4],261,false,45,21,116341,8,204,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Diabetes Mellitus, Type 2",10,{"name":18,"count":11},"Dialysis Access Malfunction",{"name":20,"count":21},"Varicose Veins",6,{"name":23,"count":21},"Knee Osteoarthritis",{"name":25,"count":26},"Chronic Venous Insufficiency",5,{"name":28,"count":26},"Cardiac Arrest",{"name":30,"count":26},"Hypertension",{"name":32,"count":26},"Stroke",[34,39,44,49],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07247201","Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients","2026-04","Allogenic expanded Natural Killer Cells",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04239859","Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis","2027-12","secukinumab",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04537689","Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis","2027-12-31","Ixekizumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07527247","Improving Vaccine Protection for Adults","2029-02-28","AS01 adjuvant",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,95,117,139,158,176,198,216,240,267,292,319,337,364,393,411,436,462,480,507,525,551,569,597,615,633,651,677,702,728,752,778,796,821,845,869,895,913,938,973,1012,1052,1082,1109,1139,1165,1183,1201,1219,1244,1268,1291,1317,1335,1360,1378,1404,1422,1440,1458,1476,1501,1519,1544,1562,1587,1615,1633,1651,1673,1701,1725,1749,1767,1791,1818,1842,1867,1892,1917,1935,1961,1979,2005],{"intervention":63,"totalTrials":64,"cells":65},"Methotrexate",2,{"EARLY_PHASE1":66,"PHASE1":69,"PHASE2":71,"PHASE3":73,"PHASE4":75,"NA":93},{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[],{"trials":72,"activeCount":68},[],{"trials":74,"activeCount":68},[],{"trials":76,"activeCount":64,"soonestReadout":42},[77,87],{"nctId":40,"briefTitle":41,"status":78,"phases":79,"primaryCompletion":42,"completion":42,"start":80,"enrollment":81,"conditions":82,"interventions":84},"NOT_YET_RECRUITING",[59],"2024-01",40,[83],"Plaque Psoriasis",[43,63,85,86],"Cyclosporin A","Acitretin",{"nctId":45,"briefTitle":46,"status":88,"phases":89,"primaryCompletion":47,"completion":47,"start":90,"enrollment":81,"conditions":91,"interventions":92},"RECRUITING",[59],"2020-12-10",[83],[48,63,85,86],{"trials":94,"activeCount":68},[],{"intervention":85,"totalTrials":64,"cells":96},{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":115},{"trials":98,"activeCount":68},[],{"trials":100,"activeCount":68},[],{"trials":102,"activeCount":68},[],{"trials":104,"activeCount":68},[],{"trials":106,"activeCount":64,"soonestReadout":42},[107,111],{"nctId":40,"briefTitle":41,"status":78,"phases":108,"primaryCompletion":42,"completion":42,"start":80,"enrollment":81,"conditions":109,"interventions":110},[59],[83],[43,63,85,86],{"nctId":45,"briefTitle":46,"status":88,"phases":112,"primaryCompletion":47,"completion":47,"start":90,"enrollment":81,"conditions":113,"interventions":114},[59],[83],[48,63,85,86],{"trials":116,"activeCount":68},[],{"intervention":86,"totalTrials":64,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":137},{"trials":120,"activeCount":68},[],{"trials":122,"activeCount":68},[],{"trials":124,"activeCount":68},[],{"trials":126,"activeCount":68},[],{"trials":128,"activeCount":64,"soonestReadout":42},[129,133],{"nctId":40,"briefTitle":41,"status":78,"phases":130,"primaryCompletion":42,"completion":42,"start":80,"enrollment":81,"conditions":131,"interventions":132},[59],[83],[43,63,85,86],{"nctId":45,"briefTitle":46,"status":88,"phases":134,"primaryCompletion":47,"completion":47,"start":90,"enrollment":81,"conditions":135,"interventions":136},[59],[83],[48,63,85,86],{"trials":138,"activeCount":68},[],{"intervention":43,"totalTrials":140,"cells":141},1,{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":156},{"trials":143,"activeCount":68},[],{"trials":145,"activeCount":68},[],{"trials":147,"activeCount":68},[],{"trials":149,"activeCount":68},[],{"trials":151,"activeCount":140,"soonestReadout":42},[152],{"nctId":40,"briefTitle":41,"status":78,"phases":153,"primaryCompletion":42,"completion":42,"start":80,"enrollment":81,"conditions":154,"interventions":155},[59],[83],[43,63,85,86],{"trials":157,"activeCount":68},[],{"intervention":48,"totalTrials":140,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":174},{"trials":161,"activeCount":68},[],{"trials":163,"activeCount":68},[],{"trials":165,"activeCount":68},[],{"trials":167,"activeCount":68},[],{"trials":169,"activeCount":140,"soonestReadout":47},[170],{"nctId":45,"briefTitle":46,"status":88,"phases":171,"primaryCompletion":47,"completion":47,"start":90,"enrollment":81,"conditions":172,"interventions":173},[59],[83],[48,63,85,86],{"trials":175,"activeCount":68},[],{"intervention":53,"totalTrials":140,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":192,"PHASE4":194,"NA":196},{"trials":179,"activeCount":68},[],{"trials":181,"activeCount":68},[],{"trials":183,"activeCount":140,"soonestReadout":52},[184],{"nctId":50,"briefTitle":51,"status":88,"phases":185,"primaryCompletion":52,"completion":52,"start":186,"enrollment":81,"conditions":187,"interventions":190},[57],"2025-11-06",[188,189],"Immune System Responses and Trained Immunity After AS01 Administration","Healthy Adult",[53,191],"YF17D",{"trials":193,"activeCount":68},[],{"trials":195,"activeCount":68},[],{"trials":197,"activeCount":68},[],{"intervention":191,"totalTrials":140,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":210,"PHASE4":212,"NA":214},{"trials":201,"activeCount":68},[],{"trials":203,"activeCount":68},[],{"trials":205,"activeCount":140,"soonestReadout":52},[206],{"nctId":50,"briefTitle":51,"status":88,"phases":207,"primaryCompletion":52,"completion":52,"start":186,"enrollment":81,"conditions":208,"interventions":209},[57],[188,189],[53,191],{"trials":211,"activeCount":68},[],{"trials":213,"activeCount":68},[],{"trials":215,"activeCount":68},[],{"intervention":38,"totalTrials":140,"cells":217},{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":234,"PHASE4":236,"NA":238},{"trials":219,"activeCount":68},[],{"trials":221,"activeCount":68},[],{"trials":223,"activeCount":140,"soonestReadout":37},[224],{"nctId":35,"briefTitle":36,"status":78,"phases":225,"primaryCompletion":37,"completion":226,"start":37,"enrollment":227,"conditions":228,"interventions":233},[56,57],"2026-09",31,[229,230,231,232],"Nasopharyngeal Carcinoma (NPC)","Minimal Residual Disease","Recurrent Nasopharyngeal Carcinoma","Maximum Tolerated Dose",[38],{"trials":235,"activeCount":68},[],{"trials":237,"activeCount":68},[],{"trials":239,"activeCount":68},[],{"intervention":241,"totalTrials":140,"cells":242},"Exelon",{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":265},{"trials":244,"activeCount":68},[],{"trials":246,"activeCount":68},[],{"trials":248,"activeCount":68},[],{"trials":250,"activeCount":68},[],{"trials":252,"activeCount":68},[253],{"nctId":254,"briefTitle":255,"status":256,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":264},"NCT00669344","RIVastigmine In Vascular cognitivE Impairment","COMPLETED",[59],"2007-04","2008-02","2006-02",50,[263],"Cognitive Impairment",[241],{"trials":266,"activeCount":68},[],{"intervention":268,"totalTrials":140,"cells":269},"Calcium Channel Blocker & Adenosine",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":290},{"trials":271,"activeCount":68},[],{"trials":273,"activeCount":68},[],{"trials":275,"activeCount":68},[],{"trials":277,"activeCount":68},[],{"trials":279,"activeCount":68},[280],{"nctId":281,"briefTitle":282,"status":256,"phases":283,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":289},"NCT00413712","Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT",[59],"2001-03","1997-01",206,[288],"Supraventricular Tachycardia",[268],{"trials":291,"activeCount":68},[],{"intervention":293,"totalTrials":140,"cells":294},"Penthrox Inhaler",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":317},{"trials":296,"activeCount":68},[],{"trials":298,"activeCount":68},[],{"trials":300,"activeCount":68},[],{"trials":302,"activeCount":68},[],{"trials":304,"activeCount":68},[305],{"nctId":306,"briefTitle":307,"status":256,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT01887951","Penthrox Versus Tramadol for SCDF",[59],"2014-08","2015-10","2014-02",380,[314],"Acute Pain",[293,316],"Tramadol",{"trials":318,"activeCount":68},[],{"intervention":316,"totalTrials":140,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":335},{"trials":322,"activeCount":68},[],{"trials":324,"activeCount":68},[],{"trials":326,"activeCount":68},[],{"trials":328,"activeCount":68},[],{"trials":330,"activeCount":68},[331],{"nctId":306,"briefTitle":307,"status":256,"phases":332,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":333,"interventions":334},[59],[314],[293,316],{"trials":336,"activeCount":68},[],{"intervention":338,"totalTrials":140,"cells":339},"Pregabalin",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":362},{"trials":341,"activeCount":68},[],{"trials":343,"activeCount":68},[],{"trials":345,"activeCount":68},[],{"trials":347,"activeCount":68},[],{"trials":349,"activeCount":68},[350],{"nctId":351,"briefTitle":352,"status":256,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":261,"conditions":357,"interventions":361},"NCT01061697","Pregabalin and Radicular Pain Study (PARPS)",[59],"2010-03","2010-04","2008-01",[358,359,360],"Cervical Spondylosis","Cervical Spondylotic Myelopathy","Cervical Spondylotic Radiculopathy",[338],{"trials":363,"activeCount":68},[],{"intervention":365,"totalTrials":140,"cells":366},"Ferric carboxymaltose",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":391},{"trials":368,"activeCount":68},[],{"trials":370,"activeCount":68},[],{"trials":372,"activeCount":68},[],{"trials":374,"activeCount":68},[],{"trials":376,"activeCount":68},[377],{"nctId":378,"briefTitle":379,"status":380,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":389},"NCT03295851","Preoperative Intravenous Iron Infusion to Reduce Post-surgical Complications: a Pilot Randomised Control Trial","UNKNOWN",[59],"2019-03","2017-11-22",60,[386,387,388],"Anemia","Major Abdominal Surgery","Pre-operative",[365,390],"Ferrous Fumarate",{"trials":392,"activeCount":68},[],{"intervention":390,"totalTrials":140,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":409},{"trials":396,"activeCount":68},[],{"trials":398,"activeCount":68},[],{"trials":400,"activeCount":68},[],{"trials":402,"activeCount":68},[],{"trials":404,"activeCount":68},[405],{"nctId":378,"briefTitle":379,"status":380,"phases":406,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":407,"interventions":408},[59],[386,387,388],[365,390],{"trials":410,"activeCount":68},[],{"intervention":412,"totalTrials":140,"cells":413},"Amoxicillin-Clavulanate 875 Mg-125 Mg Oral",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":434},{"trials":415,"activeCount":68},[],{"trials":417,"activeCount":68},[],{"trials":419,"activeCount":68},[],{"trials":421,"activeCount":68},[],{"trials":423,"activeCount":68},[424],{"nctId":425,"briefTitle":426,"status":256,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":433},"NCT04156555","Antibiotic-Associated Diarrhea and the Role of Microorganisms in the Gut",[59],"2022-10-26","2019-08-01",30,[432],"Antibiotic-associated Diarrhea",[412],{"trials":435,"activeCount":68},[],{"intervention":437,"totalTrials":140,"cells":438},"Methotrexate plus sulfasalazine",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":447,"NA":460},{"trials":440,"activeCount":68},[],{"trials":442,"activeCount":68},[],{"trials":444,"activeCount":68},[],{"trials":446,"activeCount":68},[],{"trials":448,"activeCount":68},[449],{"nctId":450,"briefTitle":451,"status":452,"phases":453,"primaryCompletion":454,"start":455,"enrollment":140,"conditions":456,"interventions":458},"NCT01659242","Leflunomide Versus Sulfasalazine\u002FMethotrexate in Rheumatoid Arthritis:an Ultrasound\u002FMagnetic Resonance Imaging Study","TERMINATED",[59],"2012-12","2012-07",[457],"Rheumatoid Arthritis",[437,459],"Leflunomide",{"trials":461,"activeCount":68},[],{"intervention":459,"totalTrials":140,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":478},{"trials":465,"activeCount":68},[],{"trials":467,"activeCount":68},[],{"trials":469,"activeCount":68},[],{"trials":471,"activeCount":68},[],{"trials":473,"activeCount":68},[474],{"nctId":450,"briefTitle":451,"status":452,"phases":475,"primaryCompletion":454,"start":455,"enrollment":140,"conditions":476,"interventions":477},[59],[457],[437,459],{"trials":479,"activeCount":68},[],{"intervention":481,"totalTrials":140,"cells":482},"fibrin sealant",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":505},{"trials":484,"activeCount":68},[],{"trials":486,"activeCount":68},[],{"trials":488,"activeCount":68},[],{"trials":490,"activeCount":68},[],{"trials":492,"activeCount":68},[493],{"nctId":494,"briefTitle":495,"status":256,"phases":496,"primaryCompletion":497,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":503},"NCT07455591","A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement",[59],"2024-08-30","2025-12-30","2024-01-01",78,[502],"Osteo Arthritis of the Knee",[481,504],"Tranexamic Acid",{"trials":506,"activeCount":68},[],{"intervention":504,"totalTrials":140,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":523},{"trials":510,"activeCount":68},[],{"trials":512,"activeCount":68},[],{"trials":514,"activeCount":68},[],{"trials":516,"activeCount":68},[],{"trials":518,"activeCount":68},[519],{"nctId":494,"briefTitle":495,"status":256,"phases":520,"primaryCompletion":497,"completion":498,"start":499,"enrollment":500,"conditions":521,"interventions":522},[59],[502],[481,504],{"trials":524,"activeCount":68},[],{"intervention":526,"totalTrials":140,"cells":527},"Adrenaline",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":547,"NA":549},{"trials":529,"activeCount":68},[],{"trials":531,"activeCount":68},[],{"trials":533,"activeCount":68},[],{"trials":535,"activeCount":68},[536],{"nctId":537,"briefTitle":538,"status":256,"phases":539,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":544,"interventions":545},"NCT00358579","Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest",[58],"2009-01","2010-01","2006-03",727,[28],[526,546],"Vasopressin",{"trials":548,"activeCount":68},[],{"trials":550,"activeCount":68},[],{"intervention":546,"totalTrials":140,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":565,"NA":567},{"trials":554,"activeCount":68},[],{"trials":556,"activeCount":68},[],{"trials":558,"activeCount":68},[],{"trials":560,"activeCount":68},[561],{"nctId":537,"briefTitle":538,"status":256,"phases":562,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":563,"interventions":564},[58],[28],[526,546],{"trials":566,"activeCount":68},[],{"trials":568,"activeCount":68},[],{"intervention":570,"totalTrials":140,"cells":571},"Curcuma longa",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":593,"NA":595},{"trials":573,"activeCount":68},[],{"trials":575,"activeCount":68},[],{"trials":577,"activeCount":68},[],{"trials":579,"activeCount":68},[580],{"nctId":581,"briefTitle":582,"status":256,"phases":583,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":589},"NCT02008981","Effect of Herbal Products on Platelet Function and Clotting",[58],"2014-04","2013-12",75,[588],"Platelet Function Test",[570,590,591,592],"Angelica sinensis","Siwu Tang","Aspirin",{"trials":594,"activeCount":68},[],{"trials":596,"activeCount":68},[],{"intervention":590,"totalTrials":140,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":611,"NA":613},{"trials":600,"activeCount":68},[],{"trials":602,"activeCount":68},[],{"trials":604,"activeCount":68},[],{"trials":606,"activeCount":68},[607],{"nctId":581,"briefTitle":582,"status":256,"phases":608,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":609,"interventions":610},[58],[588],[570,590,591,592],{"trials":612,"activeCount":68},[],{"trials":614,"activeCount":68},[],{"intervention":591,"totalTrials":140,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":629,"NA":631},{"trials":618,"activeCount":68},[],{"trials":620,"activeCount":68},[],{"trials":622,"activeCount":68},[],{"trials":624,"activeCount":68},[625],{"nctId":581,"briefTitle":582,"status":256,"phases":626,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":627,"interventions":628},[58],[588],[570,590,591,592],{"trials":630,"activeCount":68},[],{"trials":632,"activeCount":68},[],{"intervention":592,"totalTrials":140,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":647,"NA":649},{"trials":636,"activeCount":68},[],{"trials":638,"activeCount":68},[],{"trials":640,"activeCount":68},[],{"trials":642,"activeCount":68},[643],{"nctId":581,"briefTitle":582,"status":256,"phases":644,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":645,"interventions":646},[58],[588],[570,590,591,592],{"trials":648,"activeCount":68},[],{"trials":650,"activeCount":68},[],{"intervention":652,"totalTrials":140,"cells":653},"Amphotericin-B deoxycholate",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":673,"NA":675},{"trials":655,"activeCount":68},[],{"trials":657,"activeCount":68},[],{"trials":659,"activeCount":68},[],{"trials":661,"activeCount":68},[662],{"nctId":663,"briefTitle":664,"status":256,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT00361517","To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early",[58],"2007-10-30","2009-06-30","2006-06-01",47,[671],"Aspergillosis",[652],{"trials":674,"activeCount":68},[],{"trials":676,"activeCount":68},[],{"intervention":678,"totalTrials":140,"cells":679},"Sorafenib tosylate",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":698,"NA":700},{"trials":681,"activeCount":68},[],{"trials":683,"activeCount":68},[],{"trials":685,"activeCount":68},[],{"trials":687,"activeCount":68},[688],{"nctId":689,"briefTitle":690,"status":380,"phases":691,"primaryCompletion":692,"completion":692,"start":693,"enrollment":694,"conditions":695,"interventions":697},"NCT01135056","Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)",[58],"2018-07-31","2010-07",360,[696],"Hepatocellular Carcinoma",[678],{"trials":699,"activeCount":68},[],{"trials":701,"activeCount":68},[],{"intervention":703,"totalTrials":140,"cells":704},"Omeprazole",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":724,"NA":726},{"trials":706,"activeCount":68},[],{"trials":708,"activeCount":68},[],{"trials":710,"activeCount":68},[],{"trials":712,"activeCount":68},[713],{"nctId":714,"briefTitle":715,"status":256,"phases":716,"primaryCompletion":717,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":723},"NCT00519519","Optimal Dose of Omeprazole After Endoscopic Treatment of Bleeding Peptic Ulcers",[58],"2007-10","2007-11","2004-07",126,[722],"Bleeding Peptic Ulcers Disease",[703],{"trials":725,"activeCount":68},[],{"trials":727,"activeCount":68},[],{"intervention":729,"totalTrials":140,"cells":730},"Empagliflozin 10 MG",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":748,"NA":750},{"trials":732,"activeCount":68},[],{"trials":734,"activeCount":68},[],{"trials":736,"activeCount":68},[],{"trials":738,"activeCount":68},[739],{"nctId":740,"briefTitle":741,"status":452,"phases":742,"primaryCompletion":743,"completion":743,"start":744,"enrollment":64,"conditions":745,"interventions":747},"NCT03933956","Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)",[58],"2020-08-01","2020-01-09",[746],"Diabetic Nephropathies",[729],{"trials":749,"activeCount":68},[],{"trials":751,"activeCount":68},[],{"intervention":753,"totalTrials":140,"cells":754},"Hyaluronic acid",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":774,"NA":776},{"trials":756,"activeCount":68},[],{"trials":758,"activeCount":68},[],{"trials":760,"activeCount":68},[],{"trials":762,"activeCount":68},[763],{"nctId":764,"briefTitle":765,"status":380,"phases":766,"primaryCompletion":767,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":772},"NCT05076526","PRP-HA Versus HA in Knee Osteoarthritis",[57,58],"2022-11","2021-11",132,[771],"Osteoarthritis, Knee",[753,773],"Cellular Matrix platelet-rich-plasma with hyaluronic acid",{"trials":775,"activeCount":68},[],{"trials":777,"activeCount":68},[],{"intervention":773,"totalTrials":140,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":792,"NA":794},{"trials":781,"activeCount":68},[],{"trials":783,"activeCount":68},[],{"trials":785,"activeCount":68},[],{"trials":787,"activeCount":68},[788],{"nctId":764,"briefTitle":765,"status":380,"phases":789,"primaryCompletion":767,"completion":767,"start":768,"enrollment":769,"conditions":790,"interventions":791},[57,58],[771],[753,773],{"trials":793,"activeCount":68},[],{"trials":795,"activeCount":68},[],{"intervention":797,"totalTrials":140,"cells":798},"Fenofibrate",{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":805,"PHASE4":817,"NA":819},{"trials":800,"activeCount":68},[],{"trials":802,"activeCount":68},[],{"trials":804,"activeCount":68},[],{"trials":806,"activeCount":68},[807],{"nctId":808,"briefTitle":809,"status":380,"phases":810,"primaryCompletion":811,"completion":811,"start":812,"enrollment":813,"conditions":814,"interventions":816},"NCT03869931","Effects of Fenofibrate Therapy in Diabetic Nephropathy",[58],"2021-04-30","2019-03-08",300,[815,746],"Diabetes Mellitus",[797],{"trials":818,"activeCount":68},[],{"trials":820,"activeCount":68},[],{"intervention":822,"totalTrials":140,"cells":823},"Platelet rich plasma",{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":828,"PHASE3":830,"PHASE4":841,"NA":843},{"trials":825,"activeCount":68},[],{"trials":827,"activeCount":68},[],{"trials":829,"activeCount":68},[],{"trials":831,"activeCount":68},[832],{"nctId":833,"briefTitle":834,"status":380,"phases":835,"primaryCompletion":836,"completion":767,"start":768,"enrollment":837,"conditions":838,"interventions":840},"NCT05125705","PRP Versus Saline in Lateral Epicondylitis",[57,58],"2022-05",70,[839],"Lateral Epicondylitis, Unspecified Elbow",[822],{"trials":842,"activeCount":68},[],{"trials":844,"activeCount":68},[],{"intervention":846,"totalTrials":140,"cells":847},"Colchicine",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":865,"NA":867},{"trials":849,"activeCount":68},[],{"trials":851,"activeCount":68},[],{"trials":853,"activeCount":68},[],{"trials":855,"activeCount":68},[856],{"nctId":857,"briefTitle":858,"status":256,"phases":859,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":863,"interventions":864},"NCT02176460","Colchicine for Symptom and Inflammation in Knee Osteoarthritis",[57,58],"2015-09","2013-10",109,[23],[846],{"trials":866,"activeCount":68},[],{"trials":868,"activeCount":68},[],{"intervention":870,"totalTrials":140,"cells":871},"Alfuzosin",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":891,"NA":893},{"trials":873,"activeCount":68},[],{"trials":875,"activeCount":68},[],{"trials":877,"activeCount":68},[],{"trials":879,"activeCount":68},[880],{"nctId":881,"briefTitle":882,"status":883,"phases":884,"primaryCompletion":885,"completion":885,"start":886,"enrollment":68,"conditions":887,"interventions":889},"NCT00388271","Use of Alfuzosin in Stone Treatment With ESWL","WITHDRAWN",[58],"2007-12","2006-10",[888],"Urinary Calculi",[870,890],"standard treatment",{"trials":892,"activeCount":68},[],{"trials":894,"activeCount":68},[],{"intervention":890,"totalTrials":140,"cells":896},{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":903,"PHASE4":909,"NA":911},{"trials":898,"activeCount":68},[],{"trials":900,"activeCount":68},[],{"trials":902,"activeCount":68},[],{"trials":904,"activeCount":68},[905],{"nctId":881,"briefTitle":882,"status":883,"phases":906,"primaryCompletion":885,"completion":885,"start":886,"enrollment":68,"conditions":907,"interventions":908},[58],[888],[870,890],{"trials":910,"activeCount":68},[],{"trials":912,"activeCount":68},[],{"intervention":914,"totalTrials":140,"cells":915},"Levodopa",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":934,"NA":936},{"trials":917,"activeCount":68},[],{"trials":919,"activeCount":68},[],{"trials":921,"activeCount":68},[],{"trials":923,"activeCount":68},[924],{"nctId":925,"briefTitle":926,"status":256,"phases":927,"primaryCompletion":928,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":933},"NCT02073773","Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke",[58],"2015-11","2014-01",9,[932],"Ischaemic Stroke",[914],{"trials":935,"activeCount":68},[],{"trials":937,"activeCount":68},[],{"intervention":939,"totalTrials":64,"cells":940},"celgosivir",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":942,"activeCount":68},[],{"trials":944,"activeCount":68},[],{"trials":946,"activeCount":68},[947,956],{"nctId":948,"briefTitle":949,"status":256,"phases":950,"primaryCompletion":951,"completion":952,"start":455,"enrollment":261,"conditions":953,"interventions":955},"NCT01619969","Celgosivir as a Treatment Against Dengue",[56,57],"2013-03","2013-07",[954],"Dengue Fever",[939],{"nctId":957,"briefTitle":958,"status":883,"phases":959,"primaryCompletion":960,"completion":960,"start":961,"enrollment":68,"conditions":962,"interventions":963},"NCT02569827","Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore",[56,57],"2019-08-08","2018-12",[954],[964,965,966],"Celgosivir","Modipafant 50mg","Modipafant 100mg",{"trials":968,"activeCount":68},[],{"trials":970,"activeCount":68},[],{"trials":972,"activeCount":68},[],{"intervention":974,"totalTrials":64,"cells":975},"Stamaril",{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":1006,"PHASE4":1008,"NA":1010},{"trials":977,"activeCount":68},[],{"trials":979,"activeCount":68},[],{"trials":981,"activeCount":68},[982,993],{"nctId":983,"briefTitle":984,"status":256,"phases":985,"primaryCompletion":986,"completion":986,"start":987,"enrollment":988,"conditions":989,"interventions":992},"NCT03116802","Yellow Fever Vaccine on Statin\u002F Non Statin Subjects",[57],"2018-04-16","2017-03-08",37,[990,991],"Yellow Fever Vaccine","Yellow Fever",[974],{"nctId":994,"briefTitle":995,"status":380,"phases":996,"primaryCompletion":997,"completion":997,"start":998,"enrollment":837,"conditions":999,"interventions":1003},"NCT05568953","An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity",[57],"2025-10","2022-09-28",[1000,991,1001,1002],"Infectious Disease","Japanese Encephalitis","Viral Infection",[974,1004,1005],"Imojev","Ixiaro",{"trials":1007,"activeCount":68},[],{"trials":1009,"activeCount":68},[],{"trials":1011,"activeCount":68},[],{"intervention":1013,"totalTrials":64,"cells":1014},"Durvalumab",{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1016,"activeCount":68},[],{"trials":1018,"activeCount":68},[],{"trials":1020,"activeCount":68},[1021,1033],{"nctId":1022,"briefTitle":1023,"status":380,"phases":1024,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1031},"NCT03054532","Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed\u002FRefractory NK-T-cell Lymphoma",[57],"2021-01","2021-07","2017-07",22,[1030],"LYMPHOMA",[1013,1032],"Lenali",{"nctId":1034,"briefTitle":1035,"status":883,"phases":1036,"primaryCompletion":1037,"completion":1038,"start":1039,"enrollment":68,"conditions":1040,"interventions":1044},"NCT03212807","Study Of Durvalumab and Lenalidomide In R\u002FR EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL",[57],"2021-02","2023-08","2017-08",[1041,1042,1043],"EBV Related Non-Hodgkin's Lymphoma","Primary CNS Lymphoma","Primary Testicular Lymphoma",[1013,1045],"Lenalidomide",{"trials":1047,"activeCount":68},[],{"trials":1049,"activeCount":68},[],{"trials":1051,"activeCount":68},[],{"intervention":1053,"totalTrials":140,"cells":1054},"infusion of allogeneic CIK cells",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1056,"activeCount":68},[],{"trials":1058,"activeCount":68},[],{"trials":1060,"activeCount":68},[1061],{"nctId":1062,"briefTitle":1063,"status":256,"phases":1064,"primaryCompletion":454,"completion":454,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1075},"NCT00460694","Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies",[56,57],"2006-08",24,[1068,1069,1070,1071,1072,1073,1074],"Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Chronic Myeloid Leukemia","Non Hodgkin's Lymphoma","Hodgkin's Disease","Myelodysplastic Syndrome","Multiple Myeloma",[1053],{"trials":1077,"activeCount":68},[],{"trials":1079,"activeCount":68},[],{"trials":1081,"activeCount":68},[],{"intervention":1083,"totalTrials":140,"cells":1084},"Sargramostim",{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1103,"PHASE4":1105,"NA":1107},{"trials":1086,"activeCount":68},[],{"trials":1088,"activeCount":68},[],{"trials":1090,"activeCount":68},[1091],{"nctId":1092,"briefTitle":1093,"status":256,"phases":1094,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":64,"conditions":1098,"interventions":1102},"NCT04400929","Using GM-CSF as a Host Directed Therapeutic Against COVID-19",[57],"2022-01-26","2022-02-04","2020-06-02",[1099,1100,1101],"COVID","Sars-CoV2","ARDS, Human",[1083],{"trials":1104,"activeCount":68},[],{"trials":1106,"activeCount":68},[],{"trials":1108,"activeCount":68},[],{"intervention":1110,"totalTrials":140,"cells":1111},"panobinostat and bortezomib",{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1113,"activeCount":68},[],{"trials":1115,"activeCount":68},[],{"trials":1117,"activeCount":68},[1118],{"nctId":1119,"briefTitle":1120,"status":256,"phases":1121,"primaryCompletion":929,"completion":929,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1132},"NCT00901147","Study of Bortezomib and Panobinostat in Treating Patients With Relapsed\u002FRefractory Peripheral T-cell Lymphoma or NK\u002FT-cell Lymphoma",[57],"2009-11",25,[1125,1126,1127,1128,1129,1130,1131],"Peripheral T-cell Lymphoma (Not Otherwise Specified)","Angioimmunoblastic T-cell Lymphoma","Extranodal NK\u002FT-cell Lymphoma Nasal Type","Enteropathy- Type T-cell Lymphoma","Hepatosplenic T-cell Lymphoma","Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)","Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant",[1110],{"trials":1134,"activeCount":68},[],{"trials":1136,"activeCount":68},[],{"trials":1138,"activeCount":68},[],{"intervention":1140,"totalTrials":140,"cells":1141},"Benralizumab 30 MG\u002FML [Fasenra]",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1143,"activeCount":68},[],{"trials":1145,"activeCount":68},[],{"trials":1147,"activeCount":68},[1148],{"nctId":1149,"briefTitle":1150,"status":380,"phases":1151,"primaryCompletion":1038,"completion":1038,"start":1152,"enrollment":1153,"conditions":1154,"interventions":1157},"NCT04617171","Benralizumab Initiated During Severe Asthma Attack",[57],"2021-06-02",128,[1155,1156],"Asthma Attack","Asthma",[1140,1158],"Placebos",{"trials":1160,"activeCount":68},[],{"trials":1162,"activeCount":68},[],{"trials":1164,"activeCount":68},[],{"intervention":1158,"totalTrials":140,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1168,"activeCount":68},[],{"trials":1170,"activeCount":68},[],{"trials":1172,"activeCount":68},[1173],{"nctId":1149,"briefTitle":1150,"status":380,"phases":1174,"primaryCompletion":1038,"completion":1038,"start":1152,"enrollment":1153,"conditions":1175,"interventions":1176},[57],[1155,1156],[1140,1158],{"trials":1178,"activeCount":68},[],{"trials":1180,"activeCount":68},[],{"trials":1182,"activeCount":68},[],{"intervention":1004,"totalTrials":140,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1186,"activeCount":68},[],{"trials":1188,"activeCount":68},[],{"trials":1190,"activeCount":68},[1191],{"nctId":994,"briefTitle":995,"status":380,"phases":1192,"primaryCompletion":997,"completion":997,"start":998,"enrollment":837,"conditions":1193,"interventions":1194},[57],[1000,991,1001,1002],[974,1004,1005],{"trials":1196,"activeCount":68},[],{"trials":1198,"activeCount":68},[],{"trials":1200,"activeCount":68},[],{"intervention":1005,"totalTrials":140,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1204,"activeCount":68},[],{"trials":1206,"activeCount":68},[],{"trials":1208,"activeCount":68},[1209],{"nctId":994,"briefTitle":995,"status":380,"phases":1210,"primaryCompletion":997,"completion":997,"start":998,"enrollment":837,"conditions":1211,"interventions":1212},[57],[1000,991,1001,1002],[974,1004,1005],{"trials":1214,"activeCount":68},[],{"trials":1216,"activeCount":68},[],{"trials":1218,"activeCount":68},[],{"intervention":1220,"totalTrials":140,"cells":1221},"Ibrutinib-RICE",{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1223,"activeCount":68},[],{"trials":1225,"activeCount":68},[],{"trials":1227,"activeCount":68},[1228],{"nctId":1229,"briefTitle":1230,"status":380,"phases":1231,"primaryCompletion":1038,"completion":1038,"start":1232,"enrollment":1233,"conditions":1234,"interventions":1237},"NCT02955628","RICE-ibrutinib in Relapsed DLBCL",[57],"2016-12-13",34,[1235,1236],"Diffuse Large B Cell Lymphoma","Diffuse Large B-Cell Lymphoma Recurrent",[1220],{"trials":1239,"activeCount":68},[],{"trials":1241,"activeCount":68},[],{"trials":1243,"activeCount":68},[],{"intervention":1245,"totalTrials":140,"cells":1246},"Apalutamide",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1248,"activeCount":68},[],{"trials":1250,"activeCount":68},[],{"trials":1252,"activeCount":68},[1253],{"nctId":1254,"briefTitle":1255,"status":256,"phases":1256,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":430,"conditions":1259,"interventions":1261},"NCT03124433","Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer",[57],"2019-08-22","2017-06-20",[1260],"Cancer of the Prostate",[1245],{"trials":1263,"activeCount":68},[],{"trials":1265,"activeCount":68},[],{"trials":1267,"activeCount":68},[],{"intervention":1269,"totalTrials":140,"cells":1270},"Carfilzomib, , Cyclophosphamide, Dexamethasone",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1272,"activeCount":68},[],{"trials":1274,"activeCount":68},[],{"trials":1276,"activeCount":68},[1277],{"nctId":1278,"briefTitle":1279,"status":256,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":430,"conditions":1283,"interventions":1284},"NCT02217163","Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma",[57],"2020-10","2014-10",[1074],[1269],{"trials":1286,"activeCount":68},[],{"trials":1288,"activeCount":68},[],{"trials":1290,"activeCount":68},[],{"intervention":1292,"totalTrials":140,"cells":1293},"Control arm receiving normal (never before frozen) platelets as per current clinical practice",{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1295,"activeCount":68},[],{"trials":1297,"activeCount":68},[],{"trials":1299,"activeCount":68},[1300],{"nctId":1301,"briefTitle":1302,"status":256,"phases":1303,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1307,"interventions":1309},"NCT05067608","Study on the Safety and Efficacy of Cryopreserved Platelets in Hypoproliferative Thrombocytopenic Patients",[56,57],"2021-03-24","2019-10-25",17,[1308],"Hypoproliferative Thrombocytopenia",[1292,1310],"Treatment arm receiving cryopreserved platelets",{"trials":1312,"activeCount":68},[],{"trials":1314,"activeCount":68},[],{"trials":1316,"activeCount":68},[],{"intervention":1310,"totalTrials":140,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1320,"activeCount":68},[],{"trials":1322,"activeCount":68},[],{"trials":1324,"activeCount":68},[1325],{"nctId":1301,"briefTitle":1302,"status":256,"phases":1326,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1327,"interventions":1328},[56,57],[1308],[1292,1310],{"trials":1330,"activeCount":68},[],{"trials":1332,"activeCount":68},[],{"trials":1334,"activeCount":68},[],{"intervention":1336,"totalTrials":140,"cells":1337},"Daptomycin",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1354,"PHASE4":1356,"NA":1358},{"trials":1339,"activeCount":68},[],{"trials":1341,"activeCount":68},[],{"trials":1343,"activeCount":68},[1344],{"nctId":1345,"briefTitle":1346,"status":452,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":929,"enrollment":1349,"conditions":1350,"interventions":1352},"NCT01975662","Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia",[57],"2015-12",14,[1351],"Bacteremia Due to Staphylococcus Aureus",[1336,1353],"Vancomycin",{"trials":1355,"activeCount":68},[],{"trials":1357,"activeCount":68},[],{"trials":1359,"activeCount":68},[],{"intervention":1353,"totalTrials":140,"cells":1361},{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1363,"activeCount":68},[],{"trials":1365,"activeCount":68},[],{"trials":1367,"activeCount":68},[1368],{"nctId":1345,"briefTitle":1346,"status":452,"phases":1369,"primaryCompletion":1348,"completion":1348,"start":929,"enrollment":1349,"conditions":1370,"interventions":1371},[57],[1351],[1336,1353],{"trials":1373,"activeCount":68},[],{"trials":1375,"activeCount":68},[],{"trials":1377,"activeCount":68},[],{"intervention":1379,"totalTrials":140,"cells":1380},"Metformin Hydrochloride",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1398,"PHASE4":1400,"NA":1402},{"trials":1382,"activeCount":68},[],{"trials":1384,"activeCount":68},[],{"trials":1386,"activeCount":68},[1387],{"nctId":1388,"briefTitle":1389,"status":256,"phases":1390,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1396},"NCT04267809","Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection",[57],"2023-07-31","2021-10-22",32,[1395,1002,991],"Endoplasmic Reticulum Stress",[1379,1397],"Calcium and Vitamin D",{"trials":1399,"activeCount":68},[],{"trials":1401,"activeCount":68},[],{"trials":1403,"activeCount":68},[],{"intervention":1397,"totalTrials":140,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1407,"activeCount":68},[],{"trials":1409,"activeCount":68},[],{"trials":1411,"activeCount":68},[1412],{"nctId":1388,"briefTitle":1389,"status":256,"phases":1413,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1414,"interventions":1415},[57],[1395,1002,991],[1379,1397],{"trials":1417,"activeCount":68},[],{"trials":1419,"activeCount":68},[],{"trials":1421,"activeCount":68},[],{"intervention":1032,"totalTrials":140,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1434,"PHASE4":1436,"NA":1438},{"trials":1425,"activeCount":68},[],{"trials":1427,"activeCount":68},[],{"trials":1429,"activeCount":68},[1430],{"nctId":1022,"briefTitle":1023,"status":380,"phases":1431,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1028,"conditions":1432,"interventions":1433},[57],[1030],[1013,1032],{"trials":1435,"activeCount":68},[],{"trials":1437,"activeCount":68},[],{"trials":1439,"activeCount":68},[],{"intervention":965,"totalTrials":140,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1452,"PHASE4":1454,"NA":1456},{"trials":1443,"activeCount":68},[],{"trials":1445,"activeCount":68},[],{"trials":1447,"activeCount":68},[1448],{"nctId":957,"briefTitle":958,"status":883,"phases":1449,"primaryCompletion":960,"completion":960,"start":961,"enrollment":68,"conditions":1450,"interventions":1451},[56,57],[954],[964,965,966],{"trials":1453,"activeCount":68},[],{"trials":1455,"activeCount":68},[],{"trials":1457,"activeCount":68},[],{"intervention":966,"totalTrials":140,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1461,"activeCount":68},[],{"trials":1463,"activeCount":68},[],{"trials":1465,"activeCount":68},[1466],{"nctId":957,"briefTitle":958,"status":883,"phases":1467,"primaryCompletion":960,"completion":960,"start":961,"enrollment":68,"conditions":1468,"interventions":1469},[56,57],[954],[964,965,966],{"trials":1471,"activeCount":68},[],{"trials":1473,"activeCount":68},[],{"trials":1475,"activeCount":68},[],{"intervention":1477,"totalTrials":140,"cells":1478},"Caffeine Citrate 20 MG\u002FML Oral Solution",{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1480,"activeCount":68},[],{"trials":1482,"activeCount":68},[],{"trials":1484,"activeCount":68},[1485],{"nctId":1486,"briefTitle":1487,"status":1488,"phases":1489,"primaryCompletion":1490,"completion":1490,"start":1491,"enrollment":16,"conditions":1492,"interventions":1494},"NCT05232734","CaffeinICU Study - A Study on Oral Caffeine in ICU Patients With Coma","SUSPENDED",[57],"2025-12-31","2022-11-24",[1493],"Depressed GCS",[1477],{"trials":1496,"activeCount":68},[],{"trials":1498,"activeCount":68},[],{"trials":1500,"activeCount":68},[],{"intervention":1045,"totalTrials":140,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1513,"PHASE4":1515,"NA":1517},{"trials":1504,"activeCount":68},[],{"trials":1506,"activeCount":68},[],{"trials":1508,"activeCount":68},[1509],{"nctId":1034,"briefTitle":1035,"status":883,"phases":1510,"primaryCompletion":1037,"completion":1038,"start":1039,"enrollment":68,"conditions":1511,"interventions":1512},[57],[1041,1042,1043],[1013,1045],{"trials":1514,"activeCount":68},[],{"trials":1516,"activeCount":68},[],{"trials":1518,"activeCount":68},[],{"intervention":1520,"totalTrials":140,"cells":1521},"Japanese Encephalitis vaccine",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1523,"activeCount":68},[],{"trials":1525,"activeCount":68},[],{"trials":1527,"activeCount":68},[1528],{"nctId":1529,"briefTitle":1530,"status":256,"phases":1531,"primaryCompletion":1532,"completion":1348,"start":861,"enrollment":1533,"conditions":1534,"interventions":1536},"NCT01943305","The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans",[57],"2015-06",84,[991,1535],"Encephalitis, Japanese",[1520,1537],"Yellow Fever vaccine",{"trials":1539,"activeCount":68},[],{"trials":1541,"activeCount":68},[],{"trials":1543,"activeCount":68},[],{"intervention":1537,"totalTrials":140,"cells":1545},{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1547,"activeCount":68},[],{"trials":1549,"activeCount":68},[],{"trials":1551,"activeCount":68},[1552],{"nctId":1529,"briefTitle":1530,"status":256,"phases":1553,"primaryCompletion":1532,"completion":1348,"start":861,"enrollment":1533,"conditions":1554,"interventions":1555},[57],[991,1535],[1520,1537],{"trials":1557,"activeCount":68},[],{"trials":1559,"activeCount":68},[],{"trials":1561,"activeCount":68},[],{"intervention":1563,"totalTrials":140,"cells":1564},"Gentamicin",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1566,"activeCount":68},[],{"trials":1568,"activeCount":68},[],{"trials":1570,"activeCount":68},[1571],{"nctId":1572,"briefTitle":1573,"status":452,"phases":1574,"primaryCompletion":1575,"completion":1575,"start":1576,"enrollment":1577,"conditions":1578,"interventions":1580},"NCT05303909","The Immunostimulatory Effects of Gentamicin",[57],"2024-05-13","2022-05-11",33,[1579],"Healthy Volunteers",[1563],{"trials":1582,"activeCount":68},[],{"trials":1584,"activeCount":68},[],{"trials":1586,"activeCount":68},[],{"intervention":1588,"totalTrials":140,"cells":1589},"Daratumumab",{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1609,"PHASE4":1611,"NA":1613},{"trials":1591,"activeCount":68},[],{"trials":1593,"activeCount":68},[],{"trials":1595,"activeCount":68},[1596],{"nctId":1597,"briefTitle":1598,"status":380,"phases":1599,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":1604,"interventions":1606},"NCT03695744","Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma",[57],"2021-09-30","2024-04","2019-10-02",27,[1074,1605],"Myeloma",[1588,1607,1608],"Bortezomib","Dexamethasone",{"trials":1610,"activeCount":68},[],{"trials":1612,"activeCount":68},[],{"trials":1614,"activeCount":68},[],{"intervention":1607,"totalTrials":140,"cells":1616},{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1627,"PHASE4":1629,"NA":1631},{"trials":1618,"activeCount":68},[],{"trials":1620,"activeCount":68},[],{"trials":1622,"activeCount":68},[1623],{"nctId":1597,"briefTitle":1598,"status":380,"phases":1624,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":1625,"interventions":1626},[57],[1074,1605],[1588,1607,1608],{"trials":1628,"activeCount":68},[],{"trials":1630,"activeCount":68},[],{"trials":1632,"activeCount":68},[],{"intervention":1608,"totalTrials":140,"cells":1634},{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1636,"activeCount":68},[],{"trials":1638,"activeCount":68},[],{"trials":1640,"activeCount":68},[1641],{"nctId":1597,"briefTitle":1598,"status":380,"phases":1642,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":1643,"interventions":1644},[57],[1074,1605],[1588,1607,1608],{"trials":1646,"activeCount":68},[],{"trials":1648,"activeCount":68},[],{"trials":1650,"activeCount":68},[],{"intervention":1652,"totalTrials":140,"cells":1653},"Decitabine",{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1655,"activeCount":68},[],{"trials":1657,"activeCount":68},[],{"trials":1659,"activeCount":68},[1660],{"nctId":1661,"briefTitle":1662,"status":452,"phases":1663,"primaryCompletion":1664,"completion":1664,"start":693,"enrollment":21,"conditions":1665,"interventions":1666},"NCT01333449","Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients",[57],"2013-08",[1073],[1652],{"trials":1668,"activeCount":68},[],{"trials":1670,"activeCount":68},[],{"trials":1672,"activeCount":68},[],{"intervention":1674,"totalTrials":140,"cells":1675},"Chinese herbal concoction twice a day for 6 months",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1677,"activeCount":68},[],{"trials":1679,"activeCount":68},[],{"trials":1681,"activeCount":68},[1682],{"nctId":1683,"briefTitle":1684,"status":256,"phases":1685,"primaryCompletion":1686,"completion":1686,"start":1687,"enrollment":1688,"conditions":1689,"interventions":1694},"NCT01224496","Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders",[56,57],"2011-08","2009-07",38,[1690,1691,1692,1693],"Myelodysplastic Syndrome (MDS)","Aplastic Anaemia (AA)","Myelofibrosis (MF)","Thalassemia Intermedia",[1674],{"trials":1696,"activeCount":68},[],{"trials":1698,"activeCount":68},[],{"trials":1700,"activeCount":68},[],{"intervention":1702,"totalTrials":140,"cells":1703},"Autologous CIK cell",{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1719,"PHASE4":1721,"NA":1723},{"trials":1705,"activeCount":68},[],{"trials":1707,"activeCount":68},[],{"trials":1709,"activeCount":68},[1710],{"nctId":1711,"briefTitle":1712,"status":256,"phases":1713,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1718},"NCT00815321","Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy",[57],"2011-11","2008-12",11,[1070],[1702],{"trials":1720,"activeCount":68},[],{"trials":1722,"activeCount":68},[],{"trials":1724,"activeCount":68},[],{"intervention":1726,"totalTrials":140,"cells":1727},"Control",{"EARLY_PHASE1":1728,"PHASE1":1730,"PHASE2":1732,"PHASE3":1743,"PHASE4":1745,"NA":1747},{"trials":1729,"activeCount":68},[],{"trials":1731,"activeCount":68},[],{"trials":1733,"activeCount":68},[1734],{"nctId":1735,"briefTitle":1736,"status":256,"phases":1737,"primaryCompletion":929,"completion":929,"start":1738,"enrollment":1739,"conditions":1740,"interventions":1741},"NCT01246362","Efficacy Study of Pre-emptive Etoricoxib for Postoperative Pain and Functional Outcome in Total Knee Arthroplasty",[57],"2011-07",65,[23],[1726,1742],"Etoricoxib",{"trials":1744,"activeCount":68},[],{"trials":1746,"activeCount":68},[],{"trials":1748,"activeCount":68},[],{"intervention":1742,"totalTrials":140,"cells":1750},{"EARLY_PHASE1":1751,"PHASE1":1753,"PHASE2":1755,"PHASE3":1761,"PHASE4":1763,"NA":1765},{"trials":1752,"activeCount":68},[],{"trials":1754,"activeCount":68},[],{"trials":1756,"activeCount":68},[1757],{"nctId":1735,"briefTitle":1736,"status":256,"phases":1758,"primaryCompletion":929,"completion":929,"start":1738,"enrollment":1739,"conditions":1759,"interventions":1760},[57],[23],[1726,1742],{"trials":1762,"activeCount":68},[],{"trials":1764,"activeCount":68},[],{"trials":1766,"activeCount":68},[],{"intervention":1768,"totalTrials":140,"cells":1769},"bortezomib, rituximab, ifosphamide, etoposide, carboplatin",{"EARLY_PHASE1":1770,"PHASE1":1772,"PHASE2":1783,"PHASE3":1785,"PHASE4":1787,"NA":1789},{"trials":1771,"activeCount":68},[],{"trials":1773,"activeCount":68},[1774],{"nctId":1775,"briefTitle":1776,"status":256,"phases":1777,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":21,"conditions":1780,"interventions":1782},"NCT01226849","Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed\u002F Refractory Diffuse Large B-Cell Lymphoma",[56],"2014-11","2010-11",[1781],"Diffuse Large B-Cell Lymphoma",[1768],{"trials":1784,"activeCount":68},[],{"trials":1786,"activeCount":68},[],{"trials":1788,"activeCount":68},[],{"trials":1790,"activeCount":68},[],{"intervention":1792,"totalTrials":140,"cells":1793},"Tacrolimus",{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1795,"activeCount":68},[],{"trials":1797,"activeCount":68},[],{"trials":1799,"activeCount":68},[],{"trials":1801,"activeCount":68},[],{"trials":1803,"activeCount":68},[],{"trials":1805,"activeCount":68},[1806],{"nctId":1807,"briefTitle":1808,"status":256,"phases":1809,"primaryCompletion":1810,"completion":1811,"start":1812,"enrollment":1813,"conditions":1814,"interventions":1817},"NCT04825262","Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore",[60],"2024-01-16","2024-04-09","2021-02-01",74,[1815,1816],"Kidney Transplant Rejection","Kidney Transplant; Complications",[1792],{"intervention":1819,"totalTrials":140,"cells":1820},"Gentamicin Sulfate, Topical",{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1822,"activeCount":68},[],{"trials":1824,"activeCount":68},[],{"trials":1826,"activeCount":68},[],{"trials":1828,"activeCount":68},[],{"trials":1830,"activeCount":68},[],{"trials":1832,"activeCount":68},[1833],{"nctId":1834,"briefTitle":1835,"status":256,"phases":1836,"primaryCompletion":1837,"completion":498,"start":1838,"enrollment":384,"conditions":1839,"interventions":1841},"NCT05143164","Hydrocolloid Dressing for Catheter Exit Site Care in Peritoneal Dialysis Patients",[60],"2025-07-30","2022-03-11",[1840],"Peritoneal Dialysis Catheter Exit Site Infection",[1819],{"intervention":1843,"totalTrials":140,"cells":1844},"Flash Glucose Monitoring and structured education",{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1851,"PHASE4":1853,"NA":1855},{"trials":1846,"activeCount":68},[],{"trials":1848,"activeCount":68},[],{"trials":1850,"activeCount":68},[],{"trials":1852,"activeCount":68},[],{"trials":1854,"activeCount":68},[],{"trials":1856,"activeCount":68},[1857],{"nctId":1858,"briefTitle":1859,"status":256,"phases":1860,"primaryCompletion":1861,"completion":1862,"start":1863,"enrollment":1864,"conditions":1865,"interventions":1866},"NCT03837262","GLucose Monitoring Programme SingaporeE (GLiMPSE)",[60],"2020-01-23","2020-04-30","2019-03-25",35,[15],[1843],{"intervention":1868,"totalTrials":140,"cells":1869},"Paclitaxel Drug Coated Balloon",{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1878,"NA":1880},{"trials":1871,"activeCount":68},[],{"trials":1873,"activeCount":68},[],{"trials":1875,"activeCount":68},[],{"trials":1877,"activeCount":68},[],{"trials":1879,"activeCount":68},[],{"trials":1881,"activeCount":68},[1882],{"nctId":1883,"briefTitle":1884,"status":380,"phases":1885,"primaryCompletion":1886,"completion":1886,"start":1887,"enrollment":1888,"conditions":1889,"interventions":1891},"NCT04988789","Evaluation of Paclitaxel Coated Balloon in the Treatment of Dialysis Access Dysfunction",[],"2023-12-31","2020-04-01",500,[18,1890],"Kidney Failure",[1868],{"intervention":1893,"totalTrials":140,"cells":1894},"Remifentanil",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1896,"activeCount":68},[],{"trials":1898,"activeCount":68},[],{"trials":1900,"activeCount":68},[],{"trials":1902,"activeCount":68},[],{"trials":1904,"activeCount":68},[],{"trials":1906,"activeCount":68},[1907],{"nctId":1908,"briefTitle":1909,"status":256,"phases":1910,"primaryCompletion":952,"completion":952,"start":1686,"enrollment":1911,"conditions":1912,"interventions":1915},"NCT02416752","Effect of Remifentanil on the Recovery Profile After Prolonged Head and Neck Surgery",[],222,[1913,1914],"Pain","Head and Neck Disorder",[1893,1916],"choice of intra-operative opioids were left to the discretion of anesthesiologist",{"intervention":1916,"totalTrials":140,"cells":1918},{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1927,"NA":1929},{"trials":1920,"activeCount":68},[],{"trials":1922,"activeCount":68},[],{"trials":1924,"activeCount":68},[],{"trials":1926,"activeCount":68},[],{"trials":1928,"activeCount":68},[],{"trials":1930,"activeCount":68},[1931],{"nctId":1908,"briefTitle":1909,"status":256,"phases":1932,"primaryCompletion":952,"completion":952,"start":1686,"enrollment":1911,"conditions":1933,"interventions":1934},[],[1913,1914],[1893,1916],{"intervention":1936,"totalTrials":140,"cells":1937},"Flash Glucose Monitoring and Education",{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1944,"PHASE4":1946,"NA":1948},{"trials":1939,"activeCount":68},[],{"trials":1941,"activeCount":68},[],{"trials":1943,"activeCount":68},[],{"trials":1945,"activeCount":68},[],{"trials":1947,"activeCount":68},[],{"trials":1949,"activeCount":68},[1950],{"nctId":1951,"briefTitle":1952,"status":380,"phases":1953,"primaryCompletion":1954,"completion":1955,"start":1956,"enrollment":286,"conditions":1957,"interventions":1959},"NCT04564911","GLucose Monitoring Programme SingaporE, Phase 2 (GLiMPSE2)",[60],"2023-09-30","2023-12-30","2020-12-22",[15,1958],"Flash Glucose Monitoring",[1936,1960],"Capillary glucose monitoring and Education",{"intervention":1960,"totalTrials":140,"cells":1962},{"EARLY_PHASE1":1963,"PHASE1":1965,"PHASE2":1967,"PHASE3":1969,"PHASE4":1971,"NA":1973},{"trials":1964,"activeCount":68},[],{"trials":1966,"activeCount":68},[],{"trials":1968,"activeCount":68},[],{"trials":1970,"activeCount":68},[],{"trials":1972,"activeCount":68},[],{"trials":1974,"activeCount":68},[1975],{"nctId":1951,"briefTitle":1952,"status":380,"phases":1976,"primaryCompletion":1954,"completion":1955,"start":1956,"enrollment":286,"conditions":1977,"interventions":1978},[60],[15,1958],[1936,1960],{"intervention":1980,"totalTrials":140,"cells":1981},"Metformin",{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":1990,"NA":1992},{"trials":1983,"activeCount":68},[],{"trials":1985,"activeCount":68},[],{"trials":1987,"activeCount":68},[],{"trials":1989,"activeCount":68},[],{"trials":1991,"activeCount":68},[],{"trials":1993,"activeCount":68},[1994],{"nctId":1995,"briefTitle":1996,"status":256,"phases":1997,"primaryCompletion":1998,"completion":1999,"start":2000,"enrollment":2001,"conditions":2002,"interventions":2004},"NCT03503942","The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program",[60],"2024-03-31","2024-04-15","2017-12-30",751,[2003],"Pre-diabetes",[1980],{"intervention":2006,"totalTrials":140,"cells":2007},"Ropivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2009,"activeCount":68},[],{"trials":2011,"activeCount":68},[],{"trials":2013,"activeCount":68},[],{"trials":2015,"activeCount":68},[],{"trials":2017,"activeCount":68},[],{"trials":2019,"activeCount":68},[2020],{"nctId":2021,"briefTitle":2022,"status":380,"phases":2023,"primaryCompletion":2024,"completion":2025,"start":2026,"enrollment":384,"conditions":2027,"interventions":2029},"NCT04996979","Patients With Acute Hip Fractures Will Receive Either the PENG Block or no Block Respectively.",[60],"2022-05-31","2022-12-31","2021-05-24",[2028],"Hip Fractures",[2006]]